Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 620 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Probuphine Clear all
Completed Phase 1Phase 2 Interventional

ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDD

NCT01381107
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ALKS 5461, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
St. Petersburg, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Oct 21, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Tobacco Intervention in Buprenorphine Treatment

NCT01350011
View directory record Official record
Conditions
Tobacco Dependence
Interventions
Innovative System, Standard Treatment Control (STC)
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Oct 21, 2026, 1:56 AM EDT
Not yet recruiting Phase 4 Interventional

Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation

NCT07469501
View directory record Official record
Conditions
Opioid Use Disorder, Fentanyl
Interventions
Injectable buprenorphine, Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 21, 2026, 1:56 AM EDT
Completed Phase 2 Interventional

Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl

NCT05145764
View directory record Official record
Conditions
Suvorexant, Placebo, Opioid Use Disorder
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 21, 2026, 1:56 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Social Functioning in Opioid Use Disorder

NCT07044466
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
CBT4CBT-Buprenorphine
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 21, 2026, 1:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Buprenorphine-Naloxone Sublingual Spray and Suboxone® Sublingual Film in Healthy Volunteers

NCT02477267
View directory record Official record
Conditions
Opiate Dependence
Interventions
SL spray, SL film
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2015 · Synced Oct 21, 2026, 1:56 AM EDT
Recruiting Phase 3 Interventional

High Dose Buprenorphine (BUP) Induction in the Emergency Department (ED)

NCT05589181
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
High Dose Buprenorphine, Standard Buprenorphine Dose
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 21, 2026, 1:56 AM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings

NCT06854029
View directory record Official record
Conditions
HIV Infections, Opioid Use Disorder, Incarceration; Lens
Interventions
Cabotegravir Injection, Cabotegravir Pill, Buprenorphine injection, Buprenorphine Pill
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 21, 2026, 1:56 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone

NCT02666001
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068, Methadone, Buprenorphine and Norbuprenorphine
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Orlando, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 21, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Buprenorphine as a Treatment for Individuals Dependent on Analgesic Opioids

NCT00218101
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
25 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 21, 2026, 1:56 AM EDT
Active, not recruiting Not applicable Interventional

Pain Care at Home to Amplify Function (Pain CHAMP)

NCT05333341
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Misuse, Chronic Pain
Interventions
TCM, TCM plus COPES
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Little Rock, Arkansas • Aurora, Colorado • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 21, 2026, 1:56 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Better Options for Chronic Cancer Pain

NCT06574009
View directory record Official record
Conditions
Chronic Pain, Cancer Survivor, Opioid Dependence
Interventions
Multimodal pain care, Medication optimization, Buprenorphine rotation, Opioid tapering
Behavioral · Drug · Device + 1 more
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
294 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
2
States / cities
Indianapolis, Indiana • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 21, 2026, 1:56 AM EDT
Completed Not applicable Interventional Results available

Discontinuation From Chronic Opioid Therapy For Pain Using a Buprenorphine Taper

NCT02737826
View directory record Official record
Conditions
Chronic Pain, Opioid Pain Medication
Interventions
Buprenorphine Initiation - Phase I, Gabapentin + Buprenorphine - Phase II, Placebo + Buprenorphine - Phase II, Buprenorphine taper - Phase II
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 21, 2026, 1:56 AM EDT
Completed Phase 2 Interventional

INDV-6001 Multiple-Dose Pharmacokinetic Study

NCT06576843
View directory record Official record
Conditions
Moderate to Severe Opioid Use Disorder
Interventions
INDV-6001, Suboxone, Sublocade
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
San Diego, California • Miami Lakes, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 21, 2026, 1:56 AM EDT
Recruiting Not applicable Interventional

Technology-Enhanced Therapy vs. Medication Monitoring for Buprenorphine Retention in Pregnant Persons

NCT06999811
View directory record Official record
Conditions
Opioid Use Disorder, Pregnancy
Interventions
Empowering Pregnant Women and People Receiving medications for opioid use disorder (EMPWR), Medication monitoring (control)
Behavioral · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 21, 2026, 1:56 AM EDT
Withdrawn Phase 2 Interventional

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III) - 3

NCT00000328
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Opioid-Related Disorders
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 21, 2026, 1:56 AM EDT
Completed Phase 2 Interventional

Emergency Department-Initiated Buprenorphine Validation Network Trial

NCT04225598
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
CAM2038, Buprenorphine Sublingual Product
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
35
States / cities
Oakland, California • San Leandro, California • New Haven, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 21, 2026, 1:56 AM EDT
Recruiting No phase listed Observational

fMRI and Opioid Abstinence

NCT06651333
View directory record Official record
Conditions
Drug Use Disorder, Opioid Dependence, Opioid-Related Disorders, Opioid Use, Opioid Abuse
Interventions
fMRI
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Hartford, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 21, 2026, 1:56 AM EDT
Completed Early Phase 1 Interventional

Open Trial of Technology-Enhanced Behavioral Intervention for Buprenorphine Retention in Pregnant and Postpartum People

NCT06496230
View directory record Official record
Conditions
Opioid Use Disorder, Pregnancy Related
Interventions
Empowering Pregnant Women and People Receiving Medications for Opioid Use Disorder
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 21, 2026, 1:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder

NCT04976855
View directory record Official record
Conditions
Healthy Volunteer, Opioid-use Disorder
Interventions
INDV-2000, Placebo, SUBOXONE® sublingual film
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Baltimore, Maryland • DeSoto, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 21, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Results available

Cannabidiol Effects on Craving and Relapse Prevention in Opioid Use Disorder

NCT03787628
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Cannabidiol (CBD) 600 mg, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Tarzana, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 21, 2026, 1:56 AM EDT
Completed Phase 1Phase 2 Interventional

CBT4CBT for Office Based Buprenorphine

NCT03580902
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
CBT4CBT-Buprenorphine, Buprenorphine/naloxone
Behavioral · Drug
Lead sponsor
CBT4CBT, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 21, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Results available

Safety, Pharmacokinetics (PK), and Efficacy of Buprenorphine Transdermal System (BTDS) in Children

NCT01324570
View directory record Official record
Conditions
Pain
Interventions
Buprenorphine transdermal system
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
7 Years to 16 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
22
States / cities
Long Beach, California • Los Angeles, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 21, 2026, 1:56 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder

NCT02559973
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
RBP-6000, SUBOXONE Sublingual Film
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 21, 2026, 1:56 AM EDT